<DOC>
	<DOCNO>NCT00822432</DOCNO>
	<brief_summary>High dose methotrexate ( MTX ) responsible severe toxicity patient elimination plasma delay . Factors responsible MTX accumulation partly know patient still experience toxicity despite adequate measure take . Our hypothesis renal tubular secretion may impair patient . This study aim evaluate performance UCP ratio ( urinary ratio coproporphyrins ) , putative biomarker tubular secretion , predict delay MTX elimination .</brief_summary>
	<brief_title>Coproporphyrine Isomers Methotrexate Elimination</brief_title>
	<detailed_description>MTX substrate MRP2 , renal tubular transporter encode ABCC2 gene . It show single nucleotide polymorphism ( SNPs ) ABCC2 gene associate impairment MTX elimination . Mutations ABCC2 gene also responsible Dubin-Johnson syndrome , characterise absence functional MRP2 protein . Apart hyperbilirubinaemia , main biological perturbation observe disease typical increase urinary ratio coproporphyrins I ( I+ III ) ( UCP ratio ) . Our hypothesis UCP ratio could use biomarker MRP2 's activity , thus predict MTX elimination . One hundred patient treated high dose MTX recruit prospective study . Their UCP ratio measure MTX administration correlate MTX clearance . A genetic analysis conduct study five frequents SNPs ABCC2 patient .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Inclusion criterion : Patients receive HDMTX ( â‰¥1g/m2 ) primitive cerebral lymphoma , large cell lymphoma , lymphoblastic lymphoma , Burkitt 's lymphoma acute lymphoblastic leukaemia , 18 year old , Signed informed consent . Affiliated medical assurance . Able respect protocol . Effective contraception woman . Exclusion criterion : renal failure , liver failure , hepatic cytolysis , chronic respiratory deficiency , pregnancy , breastfeeding , Concomitant medication : phenytoin , probenecid , trimethoprim , phenylbutazone , salicylate , non steroid antiinflammatory , yellow fever vaccine . Patient include another study four week precede inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>biomarkers</keyword>
	<keyword>ABC transporter</keyword>
	<keyword>MRP2</keyword>
	<keyword>MTX pharmacokinetics</keyword>
</DOC>